Previous Article | Next Article ![]()
Journal of Bacteriology, May 2002, p. 2543-2545, Vol. 184, No. 9
0021-9193/02/$04.00+0 DOI: 10.1128/JB.184.9.2543-2545.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
and Milton H. Saier, Jr.*
Division of Biology, University of California at San Diego, La Jolla, California 92093-0116
Received 10 December 2001/ Accepted 8 February 2002
|
|
|---|
|
|
|---|
Several homooligomeric SMR family members in E. coli have recently been shown to confer a drug resistance phenotype (11). However, in spite of extensive efforts in this direction, no drug resistance phenotype for the distant SMR family homologues of the SugE subfamily of proteins from various gram-negative and gram-positive bacteria has been reported (8, 11, 13). The sugE gene was initially mapped to the 94-min region of the E. coli chromosome and was shown to phenotypically suppress a groEL mutation, mimicking the effect of groE overexpression when present on a multicopy plasmid (5). As demonstrated by Bishop et al. (1), a single gene, rather than the two-gene system proposed by Greener et al. (5), proved to be present at this locus.
We have cloned the E. coli sugE gene into two different vectors and here show that its overexpression in various E. coli strains confers a very specific and restricted phenotype: resistance to a subset of recognized antiseptics. Other compounds tested, including a variety of structurally related quaternary ammonium compounds as well as cationic dyes, did not appear to be substrates. Our results answer the long-standing question as to whether or not the product of the sugE gene, like several of its characterized distant homologues, is capable of functioning as a drug efflux pump. They lead to the suggestion that all members of the SMR family function in cationic drug export.
The E. coli sugE gene was cloned into the expression vectors pBAD24 and the pCR TA cloning vector, pCR2.1 (pCR2.1 TOPO; Invitrogen, Inc.). The procedure was as follows. The targeted gene was amplified by PCR with Taq polymerase using E. coli MG1655 chromosomal DNA as a template. For cloning in pBAD24, the primers (5' to 3') were CAGAATTCGATATGTCCTGGATTATCTTAG (sense) and CACTGCGCCTGGTAGTTAGTGAGTGC (antisense); for cloning in pCR2.1, the primers were CAGCGATAGTCACAAAGGTAATAG (sense) and CACTGCAGCCTGGTAGTTAGTGAGTGC (antisense). The DNA was digested with the EcoRI and PstI restriction enzymes (in pBAD24 [underlined]) with restriction sites flanking the target gene copied by PCR. The included genes were then cloned into the pBAD24 polylinker region. The pBAD24 ligation mixture was introduced into competent E. coli DH5
cells or another host. Finally, transformants were selected on the basis of ampicillin (60 µg/ml) resistance. The cloned gene(s) in pBAD24 was expressed either at low (basal) levels (in the absence of L-arabinose) or at high levels (in the presence of 0.2% L-arabinose). When cloning into pCR2.1, the amplified PCR product was designed to contain 134 bp upstream of the sugE gene. This DNA fragment was directly cloned into the vector following the instructions of the manufacturer. Recombinant plasmids were checked by restriction enzyme digestion and direct sequencing. In the case of the gene inserted into pCR2.1, the sugE gene proved to be oriented oppositely to the lacZ gene in the vector. Consequently, sugE is expressed under the control of its own promoter.
Drug assay plates were prepared with Luria-Bertani (LB) broth or M9 minimal agar, using glycerol instead of glucose as a carbon source, with or without 0.2% L-arabinose as an inducer, and various series of drug concentrations. E. coli strain DH5
and other hosts bearing the pBAD24 vector, the pCR2.1 vector, or bearing these plasmids with the gene of interest were grown overnight in LB broth with 60 µg of ampicillin/ml at 37°C with shaking (220 rpm). Subcultures were grown to an A600 of 0.6 optical density units in LB broth with 60 µg of ampicillin per ml and 0.2% L-arabinose at 37°C with shaking. These cultures were diluted 100, 10-1, and 10-2 in LB broth, and 5-µl samples of each transformant at each dilution were plated on the above-mentioned assay plates. When using LB, no inducer was required. The plates were incubated overnight at 37°C, and drug resistance was scored after 12, 18, and 24 h of growth.
Complementation experiments at various temperatures were performed by transforming E. coli strains CG3010, CG3013, and CG3014 with pCR2.1 and pCR2.1-sugE. Transformants were streaked onto LB plates containing 60 µg of ampicillin/ml, and the plates were incubated at 30, 37, or 43°C. Colony number, size, and appearance were monitored after 24 and 48 h.
The bacterial strains and plasmids used in this study are listed in Table 1. ABLE-C is an E. coli strain which reduces the copy number of a plasmid, allowing escape from toxic protein overexpression. TOP10F' is a strain that allows tight regulation of plasmid gene expression. CG3010 and CG3013 are mutated in the groEL and groES genes, respectively, while CG3014 is the isogenic parental strain (4).
|
View this table: [in a new window] |
TABLE 1. Bacterial strains and plasmids used in this study
|
, TOP10F', or ABLE-C (Table 2). Moreover, the phenotype was almost identical when the strains were examined on plates containing complex or minimal medium. Two of the several strain-medium combinations examined are presented in Table 2. The four compounds that exhibited diminished toxicity when sugE was expressed were the cetylpyridinium, cetyldimethylethyl ammonium, and cetrimide cations. They proved to be two to eight times less inhibitory when sugE was expressed. A resistance phenotype was not observed for the other quaternary ammonium compounds tested or for the cationic dyes examined (see footnote b to Table 2). The former compounds were not tested by Nishino and Yamaguchi (11), who reported the absence of a phenotype for strains expressing sugE. |
View this table: [in a new window] |
TABLE 2. MICs of various quaternary ammonium compounds in E. coli strains expressing or not expressing sugE
|
The results reported here establish that sugE gene expression can confer a highly specific drug resistance phenotype. Like most other members of the SMR family, the phenotype apparently reflects specificity for cationic compounds. Unlike the other tested members of the family, however, SugE confers a resistance phenotype only to a small subset of structurally divergent quaternary ammonium disinfectants. No other SMR family member has been shown to transport such a limited range of compounds. The YvaE homologue of Bacillus subtilis confers resistance to these compounds as well as several others not transported by E. coli SugE (3), and YvaE was the first SMR pump in B. subtilis shown to export these antiseptics. Thus, the sequence-divergent SugE protein of E. coli exhibits a previously unrecognized narrow specificity for a very specific class of compounds. The same may be predicted for orthologous gene products from other bacteria. Whether or not these represent the only physiologically important substrates of the SugE subfamily members has yet to be determined.
This work was supported by NIH grants GM64368 and GM55434.
Permanent address: Department of Life Science, Jeonju University, Chonju, Korea. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»